ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.…
ARS Pharmaceuticals Inc (SPRY) Q3 2026 Earnings Call Highlights: neffy Market Share Tops 5% as ...
ARS Pharmaceuticals (NASDAQ: SPRY) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 203 employees.
The shares were at 2.960 USD on 20 November 2026, down 63.9% over 52 weeks. Its 52-week range is 2.440 USD to 13.15 USD: the price is 77.5% below the high and 21.3% above the low.
Its market capitalisation is 297.56M USD.
ARS Pharmaceuticals reports return on equity of -149.9%, an operating margin of -161.5% and revenue up 16.0% year over year.
Its debt exceeds its cash by 58.66M USD, a debt-to-equity ratio of 0.84. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 9 March 2027.